CDIO (Cardio Diagnostics Holdings) Inventory-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cardio Diagnostics Holdings's Average Total Inventories for the quarter that ended in Dec. 2024 was $0.00 Mil. Cardio Diagnostics Holdings's Revenue for the three months ended in Dec. 2024 was $0.01 Mil. Cardio Diagnostics Holdings's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.

Cardio Diagnostics Holdings's Inventory-to-Revenue for the quarter that ended in Dec. 2024 stayed the same from Sep. 2024 (0.00) to Sep. 2024 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Cardio Diagnostics Holdings Inventory-to-Revenue Historical Data

The historical data trend for Cardio Diagnostics Holdings's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Inventory-to-Revenue Chart

Cardio Diagnostics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Inventory-to-Revenue

Cardio Diagnostics Holdings Quarterly Data
	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Inventory-to-Revenue	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Cardio Diagnostics Holdings's Inventory-to-Revenue

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardio Diagnostics Holdings's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Inventory-to-Revenue falls into.

Save Embed

;

Save Embed

;

Cardio Diagnostics Holdings Inventory-to-Revenue Calculation

Cardio Diagnostics Holdings's Inventory-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

	Inventory-to-Revenue (A: Dec. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2023 )	+	Total Inventories (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )
=	( (0	+	0)	/	1 )	/	0.035
=	0					/	0.035
=	0.00

Cardio Diagnostics Holdings's Inventory-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

	Inventory-to-Revenue (Q: Dec. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2024 )	+	Total Inventories (Q: Dec. 2024 ))	/	count )	/	Revenue (Q: Dec. 2024 )
=	( (0	+	0)	/	1 )	/	0.005
=	0					/	0.005
=	0.00

Cardio Diagnostics Holdings (NAS:CDIO) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cardio Diagnostics Holdings's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2024 )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cardio Diagnostics Holdings's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2024 )	/	Average Total Inventories (Q: Dec. 2024 )
	=	0	/	0
	=

Cardio Diagnostics Holdings Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardio Diagnostics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

311 West Superior Street, Suite 444, Chicago, IL, USA, 60654

Website

https://www.cdio.ai

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Executives

Robert Philibert	director, 10 percent owner, officer: Chief Medical Officer	400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan	officer: Chief Technology Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan	director, 10 percent owner, officer: Chief Executive Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion	director	C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman	officer: Chief Financial Officer	37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi	officer: VP of Revenue and Strategy	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim	director	C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc.	10 percent owner	15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater	officer: CEO	223 PALMER STREET, PALMER MA 01069
Allan Liu	director	1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman	director	207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc	10 percent owner	8 THE GREEN, SUITE A, DOVER DE 19901